Brief: Positive Early Study Results Help Pave Wave For Titan Pharmaceuticals To Move Forward With Its JT-09 ProNeura Development Program
01/02/2021 12:37
Feb 1 (Reuters) - Titan Pharmaceuticals Inc TTNP.O :
* POSITIVE EARLY STUDY RESULTS HELP PAVE WAVE FOR TITAN
PHARMACEUTICALS TO MOVE FORWARD WITH ITS JT-09 PRONEURA®
DEVELOPMENT PROGRAM
* TITAN PHARMACEUTICALS INC - KAPPA OPIOID AGONIST PEPTIDE,
JT-09,
HAS DEMONSTRATED HIGH POTENCY AND SPECIFICITY FOR HUMAN
KAPPA-OPIOID RECEPTOR
Source text for Eikon: ID:nPn82bH09a
Further company coverage: TTNP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Titan Pharmaceuticals
See all newsBrief: Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock
Brief: Titan Pharmaceuticals- Appoints Brynner Chiam As Acting Principal Executive Officer & Acting Principal Financial Officer Of Co
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group
Titan Pharma falls as CEO announces resignation
Brief: Titan Pharmaceuticals Enters Into Merger Agreement With Ke Sdn. Bhd.